vs
OGE ENERGY CORP.（OGE）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
登士柏西诺德的季度营收约是OGE ENERGY CORP.的1.4倍（$961.0M vs $701.7M），OGE ENERGY CORP.净利率更高（9.9% vs -15.2%，领先25.1%），登士柏西诺德同比增速更快（6.2% vs -5.8%），OGE ENERGY CORP.自由现金流更多（$83.1M vs $60.0M），过去两年OGE ENERGY CORP.的营收复合增速更高（9.7% vs 0.4%）
OGE能源集团是一家受监管的公用电力企业，核心子公司俄克拉荷马燃气电力公司为俄克拉荷马州及阿肯色州超84.3万用户提供服务，覆盖俄克拉荷马城大都会区150万居民，总部设于俄克拉荷马城市中心。集团原旗下天然气管道业务Enogex于2013年与CenterPoint Energy的中游业务合并组建为Enable Midstream。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
OGE vs XRAY — 直观对比
营收规模更大
XRAY
是对方的1.4倍
$701.7M
营收增速更快
XRAY
高出12.0%
-5.8%
净利率更高
OGE
高出25.1%
-15.2%
自由现金流更多
OGE
多$23.1M
$60.0M
两年增速更快
OGE
近两年复合增速
0.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $701.7M | $961.0M |
| 净利润 | $69.2M | $-146.0M |
| 毛利率 | 59.2% | 46.1% |
| 营业利润率 | 19.7% | -14.5% |
| 净利率 | 9.9% | -15.2% |
| 营收同比 | -5.8% | 6.2% |
| 净利润同比 | -32.1% | 66.0% |
| 每股收益（稀释后） | $0.34 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OGEXRAY
| Q4 25 | $701.7M | $961.0M | ||
| Q3 25 | $1.0B | $904.0M | ||
| Q2 25 | $719.7M | $936.0M | ||
| Q1 25 | $741.1M | $879.0M | ||
| Q4 24 | $744.7M | $905.0M | ||
| Q3 24 | $945.2M | $951.0M | ||
| Q2 24 | $644.1M | $984.0M | ||
| Q1 24 | $582.6M | $953.0M |
净利润OGEXRAY
| Q4 25 | $69.2M | $-146.0M | ||
| Q3 25 | $231.3M | $-427.0M | ||
| Q2 25 | $107.5M | $-45.0M | ||
| Q1 25 | $62.7M | $20.0M | ||
| Q4 24 | $101.9M | $-430.0M | ||
| Q3 24 | $218.7M | $-494.0M | ||
| Q2 24 | $102.3M | $-4.0M | ||
| Q1 24 | $18.6M | $18.0M |
毛利率OGEXRAY
| Q4 25 | 59.2% | 46.1% | ||
| Q3 25 | 62.2% | 48.8% | ||
| Q2 25 | 63.7% | 52.4% | ||
| Q1 25 | 56.3% | 53.0% | ||
| Q4 24 | 59.7% | 49.3% | ||
| Q3 24 | 63.0% | 52.1% | ||
| Q2 24 | 69.9% | 51.9% | ||
| Q1 24 | 60.1% | 53.1% |
营业利润率OGEXRAY
| Q4 25 | 19.7% | -14.5% | ||
| Q3 25 | 33.2% | -24.1% | ||
| Q2 25 | 25.9% | -13.7% | ||
| Q1 25 | 18.0% | 7.2% | ||
| Q4 24 | 24.5% | -56.2% | ||
| Q3 24 | 33.1% | -48.6% | ||
| Q2 24 | 27.3% | 5.1% | ||
| Q1 24 | 12.7% | 4.4% |
净利率OGEXRAY
| Q4 25 | 9.9% | -15.2% | ||
| Q3 25 | 22.5% | -47.2% | ||
| Q2 25 | 14.9% | -4.8% | ||
| Q1 25 | 8.5% | 2.3% | ||
| Q4 24 | 13.7% | -47.5% | ||
| Q3 24 | 23.1% | -51.9% | ||
| Q2 24 | 15.9% | -0.4% | ||
| Q1 24 | 3.2% | 1.9% |
每股收益（稀释后）OGEXRAY
| Q4 25 | $0.34 | $-0.74 | ||
| Q3 25 | $1.14 | $-2.14 | ||
| Q2 25 | $0.53 | $-0.22 | ||
| Q1 25 | $0.31 | $0.10 | ||
| Q4 24 | $0.50 | $-2.09 | ||
| Q3 24 | $1.09 | $-2.46 | ||
| Q2 24 | $0.51 | $-0.02 | ||
| Q1 24 | $0.09 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $200.0K | $326.0M |
| 总债务越低越好 | $5.4B | $2.3B |
| 股东权益账面价值 | $5.0B | $1.3B |
| 总资产 | $14.4B | $5.4B |
| 负债/权益比越低杠杆越低 | 1.08× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资OGEXRAY
| Q4 25 | $200.0K | $326.0M | ||
| Q3 25 | $300.0K | $363.0M | ||
| Q2 25 | $500.0K | $359.0M | ||
| Q1 25 | $26.9M | $398.0M | ||
| Q4 24 | $600.0K | $272.0M | ||
| Q3 24 | $9.9M | $296.0M | ||
| Q2 24 | $100.0K | $279.0M | ||
| Q1 24 | $4.3M | $291.0M |
总债务OGEXRAY
| Q4 25 | $5.4B | $2.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $5.1B | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益OGEXRAY
| Q4 25 | $5.0B | $1.3B | ||
| Q3 25 | $4.8B | $1.5B | ||
| Q2 25 | $4.6B | $2.0B | ||
| Q1 25 | $4.6B | $2.0B | ||
| Q4 24 | $4.6B | $1.9B | ||
| Q3 24 | $4.6B | $2.5B | ||
| Q2 24 | $4.5B | $3.1B | ||
| Q1 24 | $4.4B | $3.3B |
总资产OGEXRAY
| Q4 25 | $14.4B | $5.4B | ||
| Q3 25 | $14.3B | $5.7B | ||
| Q2 25 | $14.1B | $6.1B | ||
| Q1 25 | $14.0B | $6.0B | ||
| Q4 24 | $13.7B | $5.8B | ||
| Q3 24 | $13.5B | $6.6B | ||
| Q2 24 | $13.2B | $6.9B | ||
| Q1 24 | $12.9B | $7.1B |
负债/权益比OGEXRAY
| Q4 25 | 1.08× | 1.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.09× | 0.90× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $384.8M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $83.1M | $60.0M |
| 自由现金流率自由现金流/营收 | 11.8% | 6.2% |
| 资本支出强度资本支出/营收 | 43.0% | 4.3% |
| 现金转化率经营现金流/净利润 | 5.56× | — |
| 过去12个月自由现金流最近4个季度 | $82.7M | $104.0M |
8季度趋势，按日历期对齐
经营现金流OGEXRAY
| Q4 25 | $384.8M | $101.0M | ||
| Q3 25 | $397.8M | $79.0M | ||
| Q2 25 | $338.6M | $48.0M | ||
| Q1 25 | $15.9M | $7.0M | ||
| Q4 24 | $129.6M | $87.0M | ||
| Q3 24 | $347.1M | $141.0M | ||
| Q2 24 | $253.1M | $208.0M | ||
| Q1 24 | $83.0M | $25.0M |
自由现金流OGEXRAY
| Q4 25 | $83.1M | $60.0M | ||
| Q3 25 | $168.3M | $40.0M | ||
| Q2 25 | $64.9M | $16.0M | ||
| Q1 25 | $-233.6M | $-12.0M | ||
| Q4 24 | $-167.0M | $36.0M | ||
| Q3 24 | $103.0M | $98.0M | ||
| Q2 24 | $-70.2M | $156.0M | ||
| Q1 24 | $-143.9M | $-9.0M |
自由现金流率OGEXRAY
| Q4 25 | 11.8% | 6.2% | ||
| Q3 25 | 16.4% | 4.4% | ||
| Q2 25 | 9.0% | 1.7% | ||
| Q1 25 | -31.5% | -1.4% | ||
| Q4 24 | -22.4% | 4.0% | ||
| Q3 24 | 10.9% | 10.3% | ||
| Q2 24 | -10.9% | 15.9% | ||
| Q1 24 | -24.7% | -0.9% |
资本支出强度OGEXRAY
| Q4 25 | 43.0% | 4.3% | ||
| Q3 25 | 22.3% | 4.3% | ||
| Q2 25 | 38.0% | 3.4% | ||
| Q1 25 | 33.7% | 2.2% | ||
| Q4 24 | 39.8% | 5.6% | ||
| Q3 24 | 25.8% | 4.5% | ||
| Q2 24 | 50.2% | 5.3% | ||
| Q1 24 | 38.9% | 3.6% |
现金转化率OGEXRAY
| Q4 25 | 5.56× | — | ||
| Q3 25 | 1.72× | — | ||
| Q2 25 | 3.15× | — | ||
| Q1 25 | 0.25× | 0.35× | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.59× | — | ||
| Q2 24 | 2.47× | — | ||
| Q1 24 | 4.46× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OGE
| Residential | $238.0M | 34% |
| Commercial | $216.6M | 31% |
| Public Authority | $60.7M | 9% |
| Industrial | $59.6M | 8% |
| Oilfield | $56.6M | 8% |
| Transmission | $38.7M | 6% |
| Integrated Market | $20.4M | 3% |
| Other Contractswith Customers | $11.1M | 2% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
